Genesis Therapeutics

Genesis Therapeutics is a private, AI-native drug discovery company pioneering the use of generative AI and physics-based models to invent novel small molecule drugs. Its core technology is the GEMS (Genesis Exploration of Molecular Space) platform, anchored by foundation models like the 3D diffusion model Pearl, which is used to design compounds against challenging targets. The company has secured significant upfront payments through multi-target collaborations with partners like Gilead and Incyte, while also advancing a wholly-owned pipeline in oncology and immunology. Genesis operates at the intersection of cutting-edge AI research and experimental biology, with teams in the Bay Area, New York City, and a wet lab in San Diego.

GEMS (Genesis Exploration of Molecular Space), an AI Operating System for drug discovery integrating proprietary generative AI and physics-based models, including the 3D diffusion foundation model Pearl, for de novo design and optimization of small molecules against difficult targets.

Genesis operates in the highly competitive AI-driven drug discovery sector, facing rivals like Recursion, Exscientia, Insilico Medicine, and AbCellera. Its differentiation lies in its specific focus on 3D generative models for difficult targets and its hybrid model of internal pipeline development coupled with strategic pharma partnerships.